Skip to content

Public FDA record

Z-1143-2023: ADVIA Centaur XP and ADVIA Centaur XPT Anti-HBe2 (aHBe2) 50T- In vitro diagnostic immunoassay for the qua

Recall record Z-1143-2023 for Siemens Healthcare Diagnostics, Inc.. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-1143-2023
Company in FDA record
Siemens Healthcare Diagnostics, Inc.
FDA classification date
Feb 17, 2023
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class II

Reason stated in the source

Anti-HBe2 (aHBe2) interference with the Hepatitis B e Antigen (HBeAg) Assay, leads to elevated or reactive Hepatitis B e Antigen (HBeAg) results on samples that are non-reactive when HBeAg testing follows aHBe2 testing, regardless of whether both tests are performed on the same sample

Source facts

Action
Siemens Health issued an Urgent Medical Device Correction (UMDC CC 23-02.A.US) to US customers on 12/22/2022 . The UMDC provides instructions to customers to run the aHBe2 and HBeAg assays on separate systems if possible or to run all aHBe2 tests together and perform the Daily Cleaning Procedure before the HBeAg assay to mitigate the interference. Letter states reason for recall, health risk and action to take: Please review this letter with your Medical Director. If you have multiple ADVIA Centaur XP or ADVIA Centaur XPT systems in your laboratory, Siemens recommends testing the ADVIA Centaur aHBe2 and ADVIA Centaur HBeAg assays on separate systems to avoid potential interference. If you are testing the ADVIA Centaur HBeAg and ADVIA Centaur aHBe2 assays on the same ADVIA Centaur XP or ADVIA Centaur XPT system, test all aHBe2 samples together followed by the Daily Cleaning Procedure (DCP) prior to testing the HBeAg assay to mitigate the interference. Perform HBeAg Quality Control testing prior to HBeAg patient sample testing. Questions, contact your Siemens Healthineers Customer Care Center or your local Siemens Healthineers technical support representative.
Initiated
2022-12-22
Root cause
Under Investigation by firm
Distribution
US Nationwide distribution in the states of GA, UT.
Recall number
Z-1143-2023
Recall status
Open, Classified
CDRH record ID
198148
FDA classified
2023-02-17
Recall event number
91552

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗